Human FOLR1 Alexa Fluor® 647-conjugated Antibody Summary
Arg25-Met233
Accession # P15328
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Detection of FOLR1 in MCF-7 Human Cell Line by Flow Cytometry. MCF-7 human breast cancer cell line was stained with Mouse Anti-Human FOLR1 Alexa Fluor® 647-conjugated Monoclonal Antibody (Catalog # FAB5646R, filled histogram) or isotype control antibody (Catalog # IC002R, open histogram). View our protocol for Staining Membrane-associated Proteins.
Detection of FOLR1 in HeLa cells by Flow Cytometry HeLa cells were stained with Mouse Anti-Human FOLR1 Alexa Fluor® 647‑conjugated Monoclonal Antibody (Catalog # FAB5646R, filled histogram) or isotype control antibody (Catalog # IC002R, open histogram). View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: FOLR1
Folate Receptor 1 (FOLR1), also known as Folate Receptor alpha and Folate Binding Protein (FBP), is a 37‑42 kDa protein that mediates the cellular uptake of folic acid and reduced folates. Dietary folates are required for many key metabolic processes including nucleotide and methionine synthesis, the interconversion of glycine and serine, and histidine breakdown (1, 2). Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage (3‑6). Human FOLR1 shares 83% amino acid sequence identity with mouse and rat FOLR1. FOLR1 is predominantly expressed on epithelial cells and is dramatically up‑regulated on many carcinomas (7, 8). It is critically required during early embryogenesis as shown in knockout mice which die in utero with gross morphological defects (9). FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface (6, 10). A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk (11).
- Kelemen, L.E. (2006) Int. J. Cancer 119:243.
- Fowler, B. et al. (2001) Kidney Int. 59:S-221.
- Luhrs, C.A. et al. (1989) J. Biol. Chem. 264:21446.
- Lacey, S.W. et al. (1989) J. Clin. Invest. 84:715.
- Elwood, P.C. (1989) J. Biol. Chem. 264:14893.
- Rijnboutt, S. et al. (1996) J. Cell Biol. 132:35.
- Ross, J.F. et al. (1994) Cancer 73:2432.
- Parker, N. et al. (2005) Anal. Biochem. 338:284.
- Piedrahita, J.A. et al. (1999) Nat. Genet. 23:228.
- Paulos, C.M. et al. (2004) Mol. Pharmacol. 66:1406.
- Elwood, P.C. et al. (1991) J. Biol. Chem. 26:2346.
Product Datasheets
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
Citation for Human FOLR1 Alexa Fluor® 647-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Improving Cancer Targeting: A Study on the Effect of Dual-Ligand Density on Targeting of Cells Having Differential Expression of Target Biomarkers
Authors: Nayer Sultana, Allan E. David
International Journal of Molecular Sciences
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human FOLR1 Alexa Fluor® 647-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human FOLR1 Alexa Fluor® 647-conjugated Antibody and earn rewards!
Have you used Human FOLR1 Alexa Fluor® 647-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image